Shionogi's novel obesity drug velneperit shows Phase II promise
This article was originally published in Scrip
Shionogi has announced positive results from two separate Phase II trials of its novel oral neuropeptide Y (NPY) Y5 receptor antagonist, velneperit (S-2367), which demonstrated a reduction in body weight in clinically obese patients.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.